The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
FDA approves idecabtagene vicleucel for triple-class-exposed RRMM
On April 5, 2024, the U.S. Food and Drug Administration granted approval to idecabtagene vicleucel (ide-cel) for the treatment of triple-class-exposed relapsed/refractory multiple myeloma (RRMM) after two or more prior therapies, including an immunomodulatory agent (IMiD), proteasome inhibitor (PI), and an anti-CD38 antibody.1
This approval was based on data from the phase III KarMMa-3 (NCT03651128) clinical trial.1 The Multiple Myeloma Hub has previously reported on the trial design of KarMMa-3 here.
KarMMa-3 pivotal data1
- A total of 254 patients were randomized for treatment with ide-cel and 132 to a comparator arm consisting of standard regimens.
- At a median follow up of 15.9 months:
- Median progression-free survival (PFS) was significantly higher in the ide-cel arm at 13.3 months vs 4.4 months in the control arm.
- An overall response rate of 71% was observed with ide-cel, and a complete or stringent complete response rate of 39%.
- Median duration of overall response was 14.8 months in the ide-cel arm, and duration of complete/better response was 20 months.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content